Overview |
bs-5841R-BF405 |
MGAT5 Polyclonal Antibody, AbBy Fluor® 405 Conjugated |
WB, IF(IHC-P), IF(IHC-F), IF(ICC) |
Human |
Mouse, Rat, Dog, Chicken, Rabbit |
Specifications |
AbBy Fluor® 405 |
Rabbit |
KLH conjugated synthetic peptide derived from human MGAT5 |
201-300/741 |
Polyclonal |
IgG |
1ug/ul |
Purified by Protein A. |
Aqueous buffered solution containing 0.01M TBS (pH7.4) with 1% BSA, 0.03% Proclin300 and 50% Glycerol. |
Store at -20°C. Aliquot into multiple vials to avoid repeated freeze-thaw cycles. |
Target |
4249 |
Cytoplasm, Cell membrane |
6-mannosylglycoprotein 6-beta-N-acetylglucosaminyltransferase A; 6-N-acetylglucosaminyltransferase; Alpha 1,36 mannosylglycoprotein; Alpha 1,6 mannosylglycoprotein 6 beta N acetylglucosaminyltransferase; Alpha mannoside beta 1,6 N acetylglucosaminyltransferase; Alpha mannoside beta 1,6 N acetylglucosaminyltransferase; Alpha- mannoside beta-1,6-N-acetylglucosaminyltransferase; Alpha-1; alpha-1,36-mannosylglycoprotein; Alpha-1,6-mannosylglycoprotein 6-beta-N-acetylglucosaminyltransferase; Alpha-mannoside beta-1; alpha-mannoside beta-1,6-N-acetylglucosaminyltransferase; Beta 1,6 N acetyl glucosaminyltransferase; beta-1,6-N-acetyl-glucosaminyltransferase; GGNT5; GlcNAc T V; GlcNAc-T V; GNT V; GNT VA; GNT-V; GNTV; GNTVA; Mannoside acetylglucosaminyltransferase 5; Mannosyl alpha 1,6 glycoprotein beta 1,6 N acetyl glucosaminyltransferase; mannosyl alpha-1,6--glycoprotein beta-1,6-N-acetyl-glucosaminyltransferase; Mgat5; MGT5A_HUMAN; N acetylglucosaminyl transferase V; N acetylglucosaminyltransferase V mannosyl alpha 1,6 glycoprotein; N-acetylglucosaminyl-transferase V; N-acetylglucosaminyltransferase V. |
MGAT5 is a mannosyl (alpha-1,6-)-glycoprotein beta-1,6-N-acetyl-glucosaminyltransferase, a glycosyltransferase involved in the synthesis of protein-bound and lipid-bound oligosaccharides. Alterations of the oligosaccharides on cell surface glycoproteins cause significant changes in the adhesive or migratory behavior of a cell. Increase in the encoded protein's activity may correlate with the progression of invasive malignancies. |
Application Dilution |
WB |
1:300-5000 |
IF(IHC-P) |
1:50-200 |
IF(IHC-F) |
1:50-200 |
IF(ICC) |
1:50-200 |